Price
No data yet.
Social Signal Score
Analyst Ratings
50 analystsRevenue
$1.13B+82.29%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jacob Thaysen
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 8,600
- Beta
- 1.45
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 6.56
Financials
Revenue
$1.13B+82.3%Net Income
$220.00M+77.8%EBITDA
$335.00M+86.1%Free Cash Flow
$379.00M+90.8%EPS (diluted)
$1.43+70.2%Shares Outstanding (diluted)
154.00M+4.0%Operating Expenses
$525.00MCash & Debt
$1.34BReturn of Capital
$9.00MRevenue by Segment (annual)
$4.34BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.34B | $850.00M | $5.47 |
| 2024 | $4.37B | $-1.22B | $-7.69 |
| 2023 | $4.50B | $-1.16B | $-7.35 |
| 2022 | $4.58B | $-4.40B | $-28.05 |
| 2021 | $4.53B | $762.00M | $5.08 |
| 2020 | $3.24B | $656.00M | $4.46 |
| 2019 | $3.54B | $1.00B | $6.82 |
| 2018 | $3.33B | $826.00M | $5.62 |
| 2017 | $2.75B | $726.00M | $4.97 |
| 2016 | $2.40B | $462.65M | $3.15 |
| 2015 | $2.22B | $461.56M | $3.18 |
| 2014 | $1.86B | $353.35M | $2.61 |
| 2013 | $1.42B | $125.31M | $1.00 |
| 2012 | $1.15B | $151.25M | $1.23 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ILMN's reported EPS growth of 12.2% a year over 13 years.
- EPS in 5 years
- $9.75
- Implied price
- $243.78
- Return from $196.01
- 4.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $121.20 — -38.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 21 | 25 | 29 | 33 |
|---|---|---|---|---|---|
| 2.2% | -11.9% | -8.1% | -4.9% | -2.0% | 0.6% |
| 7.2% | -7.6% | -3.6% | -0.2% | 2.8% | 5.5% |
| 12.2% | -3.3% | 0.9% | 4.5% | 7.6% | 10.4% |
| 17.2% | 1.0% | 5.4% | 9.1% | 12.4% | 15.3% |
| 22.2% | 5.3% | 9.9% | 13.8% | 17.2% | 20.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
69-18.44%Social Signal Score
Mentions (56)
- Newsprnewswire.com·3d ago·Negative
…rithm wins Illumina a first-place finish in the 2026 Virtual Cell Challenge, hosted by Arc Institute SAN DIEGO, Nov. 19, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its BioInsight AI Lab won the 2026 Virtual Cell Challenge, hosted by Arc Institute. The company's results were powered by data from Illumina's Billion Cell Atlas and a new cellular response prediction algorithm, CellularAI, which produced highly accurate predictions of cellular responses to genetic perturb…
View source ↗ - Newszacks.com·3d ago·Positive
Illumina Stock Surges 74.8% in a Year: What's Fueling the Drive? ILMN's 74.8% stock rally reflects strong clinical sequencing demand, NovaSeq X adoption and expansion into multiomics, AI and data-driven solutions.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Illumina, Inc. (ILMN) Presents at Jefferies Global Healthcare Conference 2026 Transcript Illumina, Inc. (ILMN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsmarketbeat.com·5d ago·Positive
Illumina Sees Strong Clinical Demand, but Research Recovery Remains in Question Illumina NASDAQ: ILMN is seeing strong demand for its sequencing instruments from clinical customers, while remaining cautious about a recovery in research spending, Chief Financial Officer Ankur Dhingra said at a company news event.
View source ↗ - Newsseekingalpha.com·5d ago·Negative
Thrivent Mid Cap Stock Fund Q3 2026 Performance Review Thrivent Mid Cap Stock Fund returned (2.92%) versus the Russell Mid Cap Index's (3.00%) return. Top contributors include Veeva Systems, Illumina and Zebra Tech. Top detractors include RH and UL Solutions.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Illumina, Inc. (ILMN) Presents at 2026 UBS Global Healthcare Conference Transcript Illumina, Inc. (ILMN) Presents at 2026 UBS Global Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·13d ago·Neutral
… ctDNA at 2.5 parts per million levels with low sample input (10 nanograms) in representative studies SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced an expansion of its molecular residual disease (MRD) research portfolio with an early access program for an ultrasensitive sequencing workflow.
View source ↗ - Newsglobenewswire.com·15d ago·Neutral
…'esperienza di guida per l'era dell'intelligenza artificiale", ha dichiarato Boyuan Ni, vicepresidente di LUYUAN. Con il motto "Light up your life, Power your ride" (Illumina la vita, dai energia alla tua corsa), LYVA mira a riconnettere le persone con l'ambiente circostante attraverso una mobilità intelligente e di qualità.
View source ↗ - News (Marketaux)prnewswire.com·17d ago·Positive
Illumina selected to help bring precision medicine into everyday healthcare in Singapore SG-INSIGHT study will extend whole-genom[+232 characters]
View source ↗ - News (Marketaux)manilatimes.net·19d ago·Positive
Illumina selected to help bring precision medicine into everyday healthcare in Singapore SG-INSIGHT study will extend whole- geno[+251 characters]
View source ↗ - Newszacks.com·20d ago·Positive
3 Stocks to Watch Following Guidance Upgrades The Q3 earnings cycle continues to roll along, with several healthcare companies delivering positive results and raising their outlooks as a result.
View source ↗ - Newsprnewswire.com·20d ago·Neutral
…ating evidence to inform how precision medicine could be implemented in Singapore's healthcare system SINGAPORE, Nov. 2, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) today announced it has been selected to provide whole-genome sequencing services for the SG-INSIGHT study, a cohort under Phase III of Singapore's National Precision Medicine (NPM) programme. Expected to include approximately one in 10 Singapore residents, or around 450,000 individuals, the study is designed to generate eviden…
View source ↗ - Newszacks.com·20d ago·Positive
Why Illumina (ILMN) is a Top Growth Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newszacks.com·20d ago·Neutral
Don't Overlook Illumina (ILMN) International Revenue Trends While Assessing the Stock Explore Illumina's (ILMN) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
View source ↗ - Newszacks.com·23d ago·Neutral
ILMN Q3 Earnings Call Highlights Higher Guidance and Clinical Growth Illumina raises its 2026 guidance as strong clinical sequencing demand and NovaSeq X adoption fuel growth despite research weakness and pricing pressures.
View source ↗ - News (RSS)investing·23d ago·Neutral
Why is Illumina stock tumbling today?
View source ↗ - News (Marketaux)seekingalpha.com·23d ago·Neutral
Illumina forecasts 2026 EPS of $5.40-$5.45 while raising revenue outlook to $4.64B-$4.66B (NASDAQ:ILMN) Illumina forecasts 2026 EPS of $5.40-$5.45 while raising revenue outlook to $4.64B-$4.66B (NASDAQ:ILMN)
View source ↗ - Newszacks.com·23d ago·Neutral
Illumina (ILMN) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Illumina, Inc. (ILMN) Q3 2026 Earnings Call Transcript Illumina, Inc. (ILMN) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·24d ago·Positive
Illumina (ILMN) Q3 Earnings Beat Estimates Illumina (ILMN) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.34 per share a year ago.
View source ↗ - Newsmarketbeat.com·24d ago·Positive
Illumina Q3 Earnings Call Highlights Illumina NASDAQ: ILMN reported third-quarter results above its prior guidance, citing strong clinical sequencing demand, elevated NovaSeq X instrument placements and disciplined spending. The company raised its full-year revenue, operating-margin and earnings outlook, while executives said they remain on track toward longer-term growth targets.
View source ↗ - Newsbenzinga.com·24d ago·Positive
Illumina Q3 2026 Earnings Call Transcript Illumina (NASDAQ:ILMN) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.
View source ↗ - Newsprnewswire.com·24d ago·Neutral
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026 SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2026. Third quarter 2026 results Reported revenue was $1.13 billion for Q3 2026, up 4.2% from Q3 2025.
View source ↗ - Newszacks.com·25d ago·Neutral
Illumina (ILMN) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures Evaluate the expected performance of Illumina (ILMN) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
View source ↗ - Newsprnewswire.com·26d ago·Neutral
Illumina To Webcast Upcoming Investor Conference SAN DIEGO, Oct. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference Jefferies Global Healthcare Conference on November 17, 2026 The fireside chat is scheduled for 02:30am PT (10:30am GMT). The webcast can be accessed through the Events & Presentations section of Illumina's website at investor.illumina.com.
View source ↗ - News (RSS)seekingalpha·31d ago·Neutral
Illumina: NovaSeq X And Consumables Sustain Momentum
View source ↗ - Newsseekingalpha.com·31d ago·Positive
Illumina: NovaSeq X And Consumables Sustain Momentum Illumina (ILMN) is rated a Buy, driven by robust demand for consumables and NovaSeq X instruments, supported by favorable market dynamics and regulatory tailwinds. NovaSeq X accounts for 59% of consumable revenues, up from 44% in Q2'25, highlighting strong uptake and positioning ILMN to capture expanding diagnostic consumables market share. Management guides for FY2026 revenue of $4.60–$4.64 billion and analysts expect EPS of $5.36, reflecting…
View source ↗ - Newszacks.com·31d ago·Neutral
ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance Illumina's Q3 results may benefit from strong clinical demand, NovaSeq X adoption, instrument placements and innovations despite persistent weakness in research markets.
View source ↗ - Newsprnewswire.com·32d ago·Positive
…scale and help customers build private data lakes to drive scientific and clinical research insights SAN DIEGO, Oct. 21, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced three early-access capabilities on its BioInsight Platform that help researchers move faster from sequencing data to discovery. BioInsight Platform Workflow Orchestrator enables laboratories to operate consistent, traceable sequencing and informatics operations at scale.
View source ↗ - Newsprnewswire.com·33d ago·Neutral
Illumina To Webcast Upcoming Investor Conference SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference UBS Global Healthcare Conference on November 10, 2026 The fireside chat is scheduled for 07:15am PT (10:15am ET). The webcast can be accessed through the Events & Presentations section of Illumina's website at investor.illumina.com.
View source ↗ - Newszacks.com·37d ago·Neutral
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - Newsprnewswire.com·39d ago·Neutral
…llumina's award-winning secondary analysis across supported cloud and standard computing environment SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today debuted the Illumina BioInsight Platform, the company's first unified software environment designed to help researchers turn complex genomic and multiomic data into meaningful biological evidence. By bringing together Illumina's analysis applications, purpose-built AI innovations, and curated data resources in one enviro…
View source ↗ - Newsprnewswire.com·45d ago·Neutral
Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026 SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2026 following the close of market on Thursday, October 29, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and …
View source ↗ - Newsprnewswire.com·45d ago·Negative
… now collectively enable researchers to identify 2x as many variants with predicted biological impact SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced SpliceAI2, a new genomic AI model designed to address one of the central challenges in genomics: understanding the functional consequences of genetic variation. SpliceAI2 helps researchers identify disease-relevant splice variants that otherwise may go unnoticed.
View source ↗ - News (Marketaux)gurufocus.com·47d ago·Positive
Illumina Inc (ILMN) Shares Surge 7.6% -- What GF Score of 65 Tells Investors On October 05, 2026, Illumina <[+311 characters]
View source ↗ - News (RSS)seekingalpha·50d ago·Positive
Moderna, Illumina lead healthcare gains in September as medtech drags
View source ↗ - Newsfool.com·54d ago·Negative
Where Will Illumina Stock Be in 5 Years If Its AI Bet Pays Off? Illumina (ILMN +0.04%) is building a deeper AI strategy around the biological data created by its sequencing technology. The Billion Cell Atlas, expanding drugmaker partnerships, and improving core business could create a new growth engine if Illumina can turn its scientific advantage into recurring commercial revenue.
View source ↗ - Newszacks.com·55d ago·Negative
Is the Options Market Predicting a Spike in Illumina Stock? Investors need to pay close attention to ILMN stock based on the movements in the options market lately.
View source ↗ - Newszacks.com·59d ago·Positive
Illumina Stock Surges 94.9% YTD: What's Behind the Rally? ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.
View source ↗ - News (RSS)yahoo·63d ago·Neutral
Illumina Stock Is Up 133% This Year. Here’s Where It Could Go Further.
View source ↗ - News (RSS)zerohedge·65d ago·Neutral
…weekly inflows in three months at $63.8 billion, according to BofA, citing EPFR data through Sept. 16. Index rebalances after the close tonight include Bloom Energy, Illumina and Everpure into the S&P 500 and SpaceX will get a weighting boost from a Nasdaq 100 rebalance. In poltiics, the US is expected to hold off announcing new tariffs on China and other trading partners until after next week’s summit between Presidents Xi Jinping and Donald Trump. AI is widely expected to be a central topic at…
View source ↗ - News (RSS)investing·67d ago·Neutral
Illumina stock reaches 52-week high at 231.82 USD
View source ↗ - Newszacks.com·72d ago·Positive
Illumina (ILMN) is a Top-Ranked Momentum Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·74d ago·Neutral
3 Stocks Soon Joining the S&P 500 The S&P 500 is set for another shakeup, with Bloom Energy (BE), Everpure (P), and Illumina (ILMN) all joining in the next quarterly rebalancing near the end of September.
View source ↗ - News (RSS)yahoo·76d ago·Neutral
Illumina and Everpure to Join S&P 500 in September Rebalancing: What it Means for Investors
View source ↗ - Newszacks.com·76d ago·Positive
Illumina (ILMN) Upgraded to Buy: What Does It Mean for the Stock? Illumina (ILMN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - News (RSS)yahoo·78d ago·Neutral
Bloom Energy, Illumina, Everpure Rise On S&P 500 Inclusion
View source ↗ - News (RSS)seekingalpha·78d ago·Neutral
Bloom Energy surges on inclusion to S&P 500; Illumina, Everpure also added
View source ↗ - News (RSS)investing·78d ago·Neutral
Bloom Energy, Illumina, and Everpure set to join S&P 500 in quarterly rebalance
View source ↗ - Newsprnewswire.com·79d ago·Neutral
Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 21, 2026, to coincide with the quarterly rebalance.
View source ↗ - Newszacks.com·79d ago·Neutral
Are Robots the New Normal? Bet on these ETFs to Invest in the Future Robotics is entering a new era as AI fuels humanoid adoption, with four ETFs offering diversified exposure to the sector's growth.
View source ↗ - Newszacks.com·86d ago·Neutral
Should You Add Illumina Stock to Your Portfolio Now? ILMN's sequencing growth, oncology momentum and multiomics expansion support its outlook, though cost volatility may pressure margins.
View source ↗ - News (Marketaux)finance.yahoo.com·89d ago·Positive
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned. Illumina, the Sequencing Toll B[+299 characters]
View source ↗ - News (RSS)seekingalpha·92d ago·Positive
Illumina, Inc. Post Earnings: Buy On A Pullback
View source ↗ - Newsseekingalpha.com·92d ago·Positive
Illumina, Inc. Post Earnings: Buy On A Pullback Illumina delivered strong Q2 2026 results, beating on EPS and revenue, and raised full-year guidance for both metrics. ILMN's profitability and momentum are robust, with management emphasizing margin expansion, ongoing share buybacks, and significant cash flow. Despite a D- valuation and stagnant historical revenue, Wall Street analysts are revising growth estimates upward, anticipating a revenue breakout by 2027.
View source ↗ - Newszacks.com·102d ago·Positive
Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗
Earnings
Thu, Feb 4(in 2 months)
Consensus estimate $1.52 per share
Typical surprise +9.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$1.62 vs $1.36beat
- Thu, Jul 30$1.31 vs $1.23beat
- Thu, Apr 30$1.15 vs $1.05beat
- Thu, Feb 5$1.35 vs $1.24beat
- Thu, Oct 30$1.34 vs $1.17beat
- Thu, Jul 31$1.19 vs $1.02beat
Estimates and results for ILMN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ILMN officers and directors.
- Bought
- —
- Sold
- $415.9m
0 trades
89 trades
- Meister Keith A.sold
- Meister Keith A.sold
- Meister Keith A.sold
- Meister Keith A.sold
- Meister Keith A.sold
- Meister Keith A.sold
- Meister Keith A.sold
- Meister Keith A.sold
11 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Nov 10, 2026 (14d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Mar 10, 2026 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (24d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (65d later)Buy$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed May 15, 2025 (44d later)Buy$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Apr 21, 2025 (20d later)Buy$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Oct 1, 2024 (32d later)Sell$15,001 - $50,000
- Michael C. Burgesshouse · TX26 · disclosed Sep 24, 2024 (21d later)Sell$15,001 - $50,000
- Thomas Keanhouse · NJ07 · disclosed May 30, 2024 (41d later)Buy$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Apr 10, 2024 (30d later)Sell$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Mar 22, 2024 (11d later)Sell$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Mar 7, 2024 (24d later)Sell$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Mar 7, 2024 (24d later)Sell$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Mar 7, 2024 (27d later)Sell$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Mar 7, 2024 (24d later)Buy$15,001 - $50,000
- Michael C. Burgesshouse · TX26 · disclosed Jan 22, 2024 (20d later)Buy$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Jan 22, 2024 (20d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
